Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Multivariate analysis of factors associated with abnormal cytological findings

From: Human papillomavirus detection in women with and without human immunodeficiency virus infection in Colombia

  Abnormal Pap test result *
n (%)** Adjusted OR 95% CI
HIV; immune status CD4 cell/mm 3 count     
HIV-negative 241 (20.8) Ref  
HIV-positive, < 200 35 (16.2) 2.89 1.73-4.84
HIV-positive, 200 - 349 12 (5.6) 1.05 0.52-2.11
HIV-positive, 350 - 500 12 (5.6) 1.34 0.66-2.71
HIV-positive, > 500 9 (4.2) 1.41 0.63-3.16
HIV viral load copies/mL     
HIV-negative 241 (20.8) Ref  
HIV-positive, <4,000 49 (22.7) 1.44 0.96-2.16
HIV-positive, 4,000-99,999 8 (3.7) 1.95 0.77-4.94
HIV-positive, >100,000 11 (5.1) 8.63 2.65-28.12
HIV and ART use     
HIV-negative 241 (20.8) Ref  
HIV-positive, treatment with ART 57 (26.4) 1.57 1.06-2.32
HIV-positive, without treatment with ART 11 (5.1) 3.63 1.39-9.45
  1. OR adjusted for age, marital status, age at first intercourse, the number of lifetime sexual partners, contraceptive methods used and smoking status, Papanicolaou test, CD4-count, HIV-viral-load and antiretroviral therapy or ART.
  2. Values in bold = p < 0.05.
  3. Pap test: Papanicolaou test, 95% CI: confidence interval, OR: odds ratio, HIV: Human Immunodeficiency Virus, ART: antiretroviral therapy, ASCUS: atypical squamous cells of undetermined significance, LSIL: low grade squamous intraepithelial lesion, HSIL: high grade squamous intraepithelial lesions.
  4. *Includes ASCUS, LSIL and HSIL.
  5. **Percentages were calculated regarding HIV-positive = 216 and HIV-negative n = 1,159.